In Vitro and In Silico Investigation of Diterpenoid Alkaloids Isolated from Delphinium chitralense

This study reports the isolation of three new C20 diterpenoid alkaloids, Chitralinine A–C (1–3) from the aerial parts of Delphinium chitralense. Their structures were established on the basis of latest spectral techniques and single crystal X-rays crystallographic studies of chitralinine A described...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2022-07, Vol.27 (14), p.4348
Main Authors: Ahmad, Shujaat, Ahmad, Manzoor, Almehmadi, Mazen, Shah, Syed Adnan Ali, Khan, Farman Ali, Khan, Nasir Mehmood, Khan, Asifullah, Zainab, Halawi, Mustafa, Ahmad, Hanif
Format: Article
Language:English
Subjects:
Acetylcholinesterase
acetylcholinesterase (AChE)
Alkaloids
Alzheimer's disease
Analgesics
Brain
butyrylcholinesterase (BChE) inhibition
Cognitive ability
Crystal structure
Crystallography
Delphinium
Delphinium chitralense
Dementia
Dementia disorders
Diterpenes
diterpenoids
Enzymes
Free energy
Molecular docking
Single crystals
Spectral methods
X-ray structure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study reports the isolation of three new C20 diterpenoid alkaloids, Chitralinine A–C (1–3) from the aerial parts of Delphinium chitralense. Their structures were established on the basis of latest spectral techniques and single crystal X-rays crystallographic studies of chitralinine A described basic skeleton of these compounds. All the isolated Compounds (1–3) showed strong, competitive type inhibition against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in comparison to standard allanzanthane and galanthamine however, chitralinine-C remained the most potent with IC50 value of 11.64 ± 0.08 μM against AChE, and 24.31 ± 0.33 μM against BChE, respectively. The molecular docking reflected a binding free energy of −16.400 K Cal-mol−1 for chitralinine-C, having strong interactions with active site residues, TYR334, ASP72, SER122, and SER200. The overall findings suggest that these new diterpenoid alkaloids could serve as lead drugs against dementia-related diseases including Alzheimer’s disease.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules27144348